{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-136680","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.131421+00:00","generated_at":"2026-05-29T03:00:24.918406+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Crinetics appoints Isabel Kalofonos as CCO ahead of paltusotine launch","bullets":["Isabel Kalofonos named Chief Commercial Officer, effective Dec 16, 2024; leads paltusotine (once-daily SST2 agonist for acromegaly) launch prep and pipeline commercialization.","Compensation: $500k base salary, 40% target bonus; severance includes 9-month base pay (12-month + full target bonus if change in control within 12 months).","Expected Jan 10, 2025 grant of stock option for 100,000 shares; 25% vests Dec 16, 2025, remainder in 36 monthly installments.","Ms. Kalofonos previously CCO at Fulcrum Therapeutics; led ELAHERE launch at ImmunoGen and TAKHZYRO global launch at Takeda/Shire."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-136680","json":"https://secwatch.observer/filing/0000950170-24-136680.json","markdown":"https://secwatch.observer/filing/0000950170-24-136680.md","text":"https://secwatch.observer/filing/0000950170-24-136680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024136680/0000950170-24-136680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024136680/crnx-20241216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:00:24.918406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}